A HER2/neu vaccine-based immunotherapy for breast cancer has been reported in a pilot study by Stojadinovic A. et al. HER2/neu represents an attractive molecular target as an anticancer vaccine in breast cancer since it is overexpressed in up to 30% of breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.